Why Is ALIGNMENT HEALTHCARE (ALHC) Stock Up Today?

Alignment Healthcare (ALHC) shares rose 7.22% to $8.09, rebounding from a sharp prior-session decline. The primary driver was a reaction to the CMS 2027 Star Ratings update, which lowered the rating for the company’s California HMO contract. This development triggered a securities-fraud probe by Block & Leviton and prompted several analysts to lower their price targets.

What Happened

Block & Leviton announced it is investigating Alignment Healthcare for potential securities law violations following the CMS Star Ratings update. The release states that the update lowered the company’s California HMO contract rating. In response to the news, TD Cowen cut its price target citing EBITDA concerns, while UBS lowered its target to $9 from $22 due to utilization woes. Raymond James also cut its price target following the star rating downgrade. The stock had previously experienced a significant drop, leading to the current rebound.

What The Data Shows

Alignment Healthcare has a market capitalization of $1.6 billion and a P/E ratio of 38.2. Trailing twelve-month revenue grew 37.2%, though the net margin stands at 0.9%. The stock has a beta of 1.14 and a 52-week range of $6.01 to $25.12. Over the last eight sessions, the stock moved up 3.5% from $7.82 to $8.09. The 52-week tape recorded 22 fresh 52-week highs on October 12, 2026. Insider activity shows zero buys and eight sells totaling $17.4 million in the last 90 days, with the most recent filing on October 7, 2026. CEO John E. Kao sold shares on September 14, 2026, and Chief Medical Officer Kim Hyong sold on October 6, 2026. Congressional disclosures show two sales and one buy in the last 90 days.

What To Watch

Investors will monitor the outcome of the Block & Leviton investigation and further analyst reactions to the Star Ratings update. The company’s ability to manage utilization costs and EBITDA margins will be key factors in future price target adjustments.